Cannapharmarx Financials
Cannapharmarx (CPMD) reported $1.4M in revenue for fiscal year 2025, up 66.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is being overwhelmed by negative unit economics and a liability-funded balance sheet.
From FY2023 to FY2025, operating cash burn improved from-$2.27M to-$789K . Yet net income moved from$3.69M to-$11.13M , and FY2025 interest expense still exceeded revenue, showing that earnings and cash are diverging while financing costs remain heavier than the top line.
FY2025 sales reached
Liquidity remains extremely thin: cash was just
Financial Health Signals
Cannapharmarx does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cannapharmarx scores -28.93, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7M) relative to total liabilities ($37.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cannapharmarx passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Cannapharmarx reported a net loss of $11.1M while operations used $789K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cannapharmarx reported an operating loss of $3.3M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cannapharmarx generated $1.4M in revenue in fiscal year 2025. This represents an increase of 66.1% from the prior year.
Cannapharmarx reported -$11.1M in net income in fiscal year 2025. This represents a decrease of 12.4% from the prior year.
Cannapharmarx earned -$0.02 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cannapharmarx recorded an outflow of $795K in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 53.2% from the prior year.
Cannapharmarx held $2K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Cannapharmarx invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CPMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $276K-56.0% | $627K+352.6% | $139K-78.9% | $657K+183.5% | $232K-30.9% | $335K | N/A | $312K |
| Cost of Revenue | $415K-60.0% | $1.0M+57.2% | $660K-39.8% | $1.1M+28.6% | $853K+1.8% | $838K | N/A | $668K |
| Gross Profit | -$138K+66.2% | -$409K+21.4% | -$521K-18.4% | -$440K+29.2% | -$621K-23.6% | -$503K | N/A | -$356K |
| SG&A Expenses | $83K+131.0% | $36K-84.4% | $230K+57.9% | $145K+91.5% | $76K+96.6% | $39K | N/A | $51K |
| Operating Income | -$379K+44.5% | -$682K+23.6% | -$894K+4.5% | -$936K-11.3% | -$841K-24.1% | -$678K | N/A | -$516K |
| Interest Expense | $185K-61.1% | $476K+165.1% | $179K-64.6% | $506K-23.0% | $658K+6.8% | $616K | N/A | $632K |
| Income Tax | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$1.9M-399.7% | -$382K+94.9% | -$7.5M-410.9% | -$1.5M-4.6% | -$1.4M-104.7% | -$691K+81.5% | -$3.7M-2085.4% | $188K |
| EPS (Diluted) | $0.00 | $0.00+100.0% | -$0.01 | $0.00 | $0.00 | $0.00+100.0% | -$0.01 | $0.00 |
Not reported in any period shown, so not listed: R&D Expenses.
CPMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.9M+4.7% | $6.6M-6.2% | $7.0M-39.6% | $11.6M+1.3% | $11.5M+2.1% | $11.2M+3.7% | $10.8M-7.2% | $11.7M |
| Current Assets | $1.3M+43.4% | $930K-29.1% | $1.3M-10.8% | $1.5M+22.8% | $1.2M-3.1% | $1.2M+21.4% | $1.0M-32.0% | $1.5M |
| Cash & Equivalents | $555-12.3% | $633-64.9% | $2K+94.6% | $927-94.5% | $17K+1305.2% | $1K-44.0% | $2K-69.2% | $7K |
| Inventory | $1.3M+44.7% | $903K-19.0% | $1.1M+29.1% | $864K-17.2% | $1.0M+9.7% | $951K-4.5% | $996K-18.3% | $1.2M |
| Accounts Receivable | $7K-1.9% | $7K-95.8% | $164K-72.1% | $588K+414.7% | $114K-56.5% | $263K+14947.3% | $2K-99.0% | $183K |
| Total Liabilities | $37.7M+2.4% | $36.9M-0.9% | $37.2M+8.9% | $34.1M+0.3% | $34.0M+7.3% | $31.7M+3.6% | $30.6M+8.4% | $28.3M |
| Current Liabilities | $32.6M+3.4% | $31.5M-0.3% | $31.6M+10.9% | $28.5M-1.6% | $29.0M+7.7% | $26.9M+4.4% | $25.8M+14.4% | $22.5M |
| Total Equity | -$30.8M-1.9% | -$30.3M-0.4% | -$30.2M-33.9% | -$22.5M+0.3% | -$22.6M-10.1% | -$20.5M-3.5% | -$19.8M-19.4% | -$16.6M |
| Retained Earnings | -$114.6M-1.7% | -$112.7M-0.3% | -$112.3M-7.2% | -$104.8M-1.4% | -$103.3M-1.4% | -$101.9M-0.7% | -$101.2M-3.8% | -$97.4M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CPMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$127K+47.7% | -$244K-123.0% | $1.1M+232.2% | -$803K-79.8% | -$446K+25.8% | -$601K-234.3% | -$180K+66.7% | -$541K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$180K | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $1.7M | N/A |
| Financing Cash Flow | $182K-24.8% | $242K+113.1% | -$1.9M-335.8% | $787K+70.2% | $462K-23.0% | $600K+139.4% | -$1.5M-382.8% | $539K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CPMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -50.1%+15.1pp | -65.3% | -375.9% | -67.0% | -268.2% | -149.9% | N/A | -114.1% |
| Operating Margin | -137.2% | -108.7% | -644.6% | -142.5% | -363.1% | -202.1% | N/A | -165.3% |
| Net Margin | -691.1% | -60.9% | -5445.9% | -225.1% | -610.3% | -205.9% | N/A | 60.4% |
| Return on Assets | -27.7%-21.9pp | -5.8%+101.8pp | -107.6%-94.9pp | -12.7%-0.4pp | -12.3%-6.2pp | -6.2%+28.4pp | -34.5%-36.1pp | 1.6% |
| Current Ratio | 0.040.0x | 0.030.0x | 0.040.0x | 0.050.0x | 0.040.0x | 0.050.0x | 0.040.0x | 0.07 |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$30.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Cannapharmarx Ranks
Frequently Asked Questions
What is Cannapharmarx's annual revenue?
Cannapharmarx (CPMD) reported $1.4M in total revenue for fiscal year 2025. This represents a 66.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cannapharmarx's revenue growing?
Cannapharmarx (CPMD) revenue grew by 66.1% year-over-year, from $820K to $1.4M in fiscal year 2025.
Is Cannapharmarx profitable?
No, Cannapharmarx (CPMD) reported a net income of -$11.1M in fiscal year 2025.
What is Cannapharmarx's free cash flow?
Cannapharmarx (CPMD) recorded an outflow of $795K in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cannapharmarx's operating cash flow?
Cannapharmarx (CPMD) recorded an outflow of $789K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cannapharmarx's total assets?
Cannapharmarx (CPMD) had $7.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cannapharmarx's capital expenditures?
Cannapharmarx (CPMD) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cannapharmarx's current ratio?
Cannapharmarx (CPMD) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Cannapharmarx's return on assets (ROA)?
Cannapharmarx (CPMD) had a return on assets of -158.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cannapharmarx's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cannapharmarx (CPMD) held $2K in cash, cash equivalents and investments, and reported an operating cash outflow of $789K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Cannapharmarx's debt-to-equity ratio negative or not reported?
Cannapharmarx (CPMD) has negative shareholder equity of -$30.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cannapharmarx's Altman Z-Score?
Cannapharmarx (CPMD) has an Altman Z-Score of -28.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cannapharmarx's Piotroski F-Score?
Cannapharmarx (CPMD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cannapharmarx's earnings high quality?
Cannapharmarx (CPMD) reported a net loss of $11.1M while operations used $789K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cannapharmarx cover its interest payments?
Cannapharmarx (CPMD) reported an operating loss of $3.3M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.